Biotech Completes Last Patient Visit in Phase2b Osteosarcoma Trial
Source: Jason Kolbert  (10/3/24)
Following OS Therapies Inc.'s (OSTX:NYSEAMERICAN) announcement that the last patient enrolled in their Phase 2b trial for OST-HER2 in recurred, resected Osteosarcoma (OS) has completed their final radiographical evaluation, the company received a Buy rating and high target price from EF Hutton. More >

New Jersey Biotech Reports Positive Survival Data
Source: Dr. Joseph Pantginis  (10/2/24)
H.C. Wainwright & Co. analysts Dr. Joseph Pantginis gave PDS Biotechnology Corp. (PDSB:NASDAQ) a Buy rating and large target price. More >

California Biotech's Target Price 200% Higher Than Current
Source: Jason Kolbert  (9/30/24)
F Hutton analyst Jason Kolbert gave Anixa Biosciences Inc. (ANIX: NASDAQ) a high target price after it had announced it would be amending the protocol for its ongoing CAR-T therapy clinical trial for ovarian cancer, allowing for a second dose in certain patients. More >

Target Price Raised on Biotech Co.
Source: Robert Burns  (9/25/24)
In an updated assessment of Zymeworks Inc.'s (ZYME:NYSE; ZYME:TSX) pipeline potential and upcoming catalysts, H.C. Wainwright & Co. analysts raised their target price on the company. More >

CA Pharma Co. Reports Positive Phase 3 Data for Schizophrenia Treatment
Source: Jason Kolbert  (9/23/24)
Reviva Pharmaceuticals Holdings Inc. (RVPH: NASDAQ) recently reported positive Phase 3 data for its Schizophrenia treatment. The company also noted it intends to file an NDA in the first quarter of 2026, according to an EF Hutton Research note. More >

AI Collaboration to Streamline Healthcare Administration and Improve Patient Outcomes
Source: Streetwise Reports  (9/19/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has formally entered a collaborative agreement with UK-based AI healthcare technology company SPRYT Limited. Read how this partnership aims to change the way patients interact with their healthcare providers. More >

Revolutionizing Chronic Disease Treatment Through Regenerative Medicine
Source: Streetwise Reports  (9/17/24)
A regenerative medicine therapeutics company focused on developing technologies to address chronic diseases through a regenerative approach, Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) is focused on reforming healthcare through technology. See why experts and analysts are praising this company's potential. More >

Co's. Cell Pouch Performs Well in Study
Source: Dr. Douglas Loe  (9/16/24)
Data show the device keeps the incorporated therapeutic cells alive and functioning for at least five years, noted a Leede Financial Inc. report. More >

Implanted Cell Device Reaches 5 Year Milestone
Source: Stefan Quenneville  (9/16/24)
This pouch, loaded with pancreatic islet cells, is being evaluated in patients with insulin-dependent Type 1 diabetes, noted a Ventum Capital Markets report. More >

Trial Data Help Position Cell Pouch for Commercial Success
Source: Dr. Joseph Pantginis  (9/16/24)
The upside implied in the target price on this Canadian firm, developing regenerative medicine platform technologies, is 1,900%, noted an H.C. Wainwright & Co. report. More >

Is It Now Time To Buy This Biotech Stock?
Source: Clive Maund  (9/16/24)
Technical Analyst Clive Maund shares his thoughts on Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) to explain why he believes it is a good stock to accumulate, between the current price and recent lows. More >

California Biotech Reports Positive QOL Improvements in Program
Source: Dr. Jonathan Aschoff  (9/13/24)
With Ontrak Inc.'s (OTRK:NASDAQ) significant results from the first six months of data collected through its implementation of ReQoL, Roth MKM analyst Dr, Jonathan Schoff gave the company a Buy rating. More >

Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment
Source: Streetwise Reports  (9/12/24)
Clinical stage biotechnology company Sernova Corp. (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) has released new data that show success in using its Cell Pouch Transplant System to help Type 1 diabetes patients reach insulin independence. One author says the company is David taking on Goliath in the race for a cure. More >

Biotech Working on 'Functional Cure' for Type 1 Diabetes
Source: Streetwise Reports  (9/10/24)
Clinical-stage biotechnology company Sernova Corp.'s (SVA:TSX.V; SEOVF:OTCMKTS; XETRA:PSH) Cell Pouch implantable technology can act as a "pseudo-organ," delivering therapeutic cells to the body. Find out why one newsletter author thinks the stock could deliver a big payoff for shareholders and for patients. More >

MA Biotech Reports Positive Meeting with FDA
Source: Dr. Benjamin Paluch  (9/9/24)
Replimune Group Inc.'s (REPL:NASDAQ) announced a successful pre-Biologics License Application (BLA) meeting with the FDA, according to a Roth MKM research note. More >

Healthcare Tech Firm and Leading University to Join Forces
Source: Streetwise Reports  (9/7/24)
The parties intend to develop artificial intelligence-backed solutions to a problem in healthcare, for expanded use throughout and beyond the United Kingdom. Find out why one analyst is bullish on this company and its proprietary platform. More >

Mass. Biopharma Reports Positive Data and Announces New Program
Source: Dr. David Nierengarten  (9/6/24)
Wedbush analysts noted that they would be buyers ahead of Vor Biopharma Inc.'s (VOR:NASDAQ) planned regulatory updates and likely further data readouts. More >

Pharma Co. Enrolls First Patient in Trial
Source: Dr. Joseph Pantginis  (9/5/24)
Rigel Pharmaceuticals (RIGL:NASDAQ) recently announced the enrollment of the first patient in a Phase 1b/2 trial assessing decitabine and venetoclax in combination with Rezlidhia in mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), according to an H.C. Wainwright & Co. research note, which rated the stock a Buy. More >

Florida Biotech Completes Enrollment in 'Pivotal' Drug Trial
Source: Streetwise Reports  (8/16/24)
Florida-based Cyclo Therapeutics Inc. (CYTH:NASDAQ) says it has completed enrollment in its "pivotal" TransportNPC trial of Niiemann-Pick Type C1, a rare progressive genetic disorder. Find out why analysts are recommending the stock. More >

Long Term Care Co.'s Target Price Raised
Source: Dr. Douglas Loe  (8/14/24)
Leede Financial Inc. recently raised the target price on Extendicare Inc. (EXE:TSX) based on FQ24 financial results. More >

Promising Clinical Data and Strategic Partnerships Propel Oncology Co.
Source: Streetwise Reports  (8/9/24)
Elevation Oncology Inc.(ELEV:NASDAQ) reported its second-quarter 2024 financial results on August 6, highlighting significant progress in its clinical trials and ongoing business achievements. Read on to see why three experts believe this stock is a Buy. More >

AI Healthcare Co. Signs Partnership With Large Regional Health Plan
Source: Dr. Jonathan Aschoff  (8/9/24)
Ontrak Inc. (NASDAQ: OTRK) announced it had signed a two-year strategic partnership with a large, northeast regional health plan focused on the plan's New York State members. This development comes as the company continues to rebuild its client base following a significant customer loss in Q1 2024, noted a Roth MKM research note. More >

Boston Biotech Reports Promising Interim Data
Source: Dr. Swayampakula Ramakanth  (8/7/24)
Interim efficacy data reported for Elevation Oncology Inc.'s (ELEV:NASDAQ) EO-3021 as a monotherapy is competitive and potentially could be superior as a combination therapy, according to an H.C. Wainwright & Co. research note. More >

New Firmware Update Enhances Counter-Drone Capabilities
Source: Streetwise Reports  (8/6/24)
DroneShield Ltd. (DRO:ASX; DRSHF:OTC) has released its latest firmware update for its full range of Radio Frequency (RF) sensors. Read about what this advancement means for the technological power of the company's product line. More >

AI Healthcare Co. Creates AI Pharmacy Assistant
Source: Streetwise Reports  (8/2/24)
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced it will roll out a new AI (artificial intelligence) Pharmacy Assistant to support pharmacists. One analyst says the company has positioned itself as a "central go-to resource." More >